These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1310 related items for PubMed ID: 17904457

  • 1. Obesity paradox in patients with hypertension and coronary artery disease.
    Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, Pepine CJ.
    Am J Med; 2007 Oct; 120(10):863-70. PubMed ID: 17904457
    [Abstract] [Full Text] [Related]

  • 2. The relationship of body mass index to outcomes after percutaneous coronary intervention.
    Shubair MM, Prabhakaran P, Pavlova V, Velianou JL, Sharma AM, Natarajan MK.
    J Interv Cardiol; 2006 Oct; 19(5):388-95. PubMed ID: 17020562
    [Abstract] [Full Text] [Related]

  • 3. Relation of body mass index to outcome in patients with known or suspected coronary artery disease.
    Galal W, van Domburg RT, Feringa HH, Schouten O, Elhendy A, Bax JJ, Awara AM, Klein J, Poldermans D.
    Am J Cardiol; 2007 Jun 01; 99(11):1485-90. PubMed ID: 17531566
    [Abstract] [Full Text] [Related]

  • 4. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
    Bangalore S, Messerli FH, Franklin SS, Mancia G, Champion A, Pepine CJ.
    Eur Heart J; 2009 Jun 01; 30(11):1395-401. PubMed ID: 19351690
    [Abstract] [Full Text] [Related]

  • 5. Predictors of adverse outcome among patients with hypertension and coronary artery disease.
    Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancia G, Coca A, Cooper-DeHoff RM, Handberg E, Gaxiola E, Sleight P, Conti CR, Hewkin AC, Tavazzi L, INVEST Investigators.
    J Am Coll Cardiol; 2006 Feb 07; 47(3):547-51. PubMed ID: 16458134
    [Abstract] [Full Text] [Related]

  • 6. The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative.
    Diercks DB, Roe MT, Mulgund J, Pollack CV, Kirk JD, Gibler WB, Ohman EM, Smith SC, Boden WE, Peterson ED.
    Am Heart J; 2006 Jul 07; 152(1):140-8. PubMed ID: 16824844
    [Abstract] [Full Text] [Related]

  • 7. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients--findings from the International Verapamil SR/Trandolapril Study (INVEST).
    Cooper-DeHoff RM, Aranda JM, Gaxiola E, Cangiano JL, Garcia-Barreto D, Conti CR, Hewkin A, Pepine CJ, INVEST Investigators.
    Am Heart J; 2006 May 07; 151(5):1072-9. PubMed ID: 16644338
    [Abstract] [Full Text] [Related]

  • 8. Influence of obesity on outcomes in atrial fibrillation: yet another obesity paradox.
    Badheka AO, Rathod A, Kizilbash MA, Garg N, Mohamad T, Afonso L, Jacob S.
    Am J Med; 2010 Jul 07; 123(7):646-51. PubMed ID: 20609687
    [Abstract] [Full Text] [Related]

  • 9. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW, INVEST Investigators.
    JAMA; 2003 Dec 03; 290(21):2805-16. PubMed ID: 14657064
    [Abstract] [Full Text] [Related]

  • 10. A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in patients treated with a calcium antagonist versus an atenolol hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST).
    Ried LD, Tueth MJ, Handberg E, Kupfer S, Pepine CJ, INVEST Study Group.
    Psychosom Med; 2005 Dec 03; 67(3):398-406. PubMed ID: 15911902
    [Abstract] [Full Text] [Related]

  • 11. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
    Cooper-Dehoff R, Cohen JD, Bakris GL, Messerli FH, Erdine S, Hewkin AC, Kupfer S, Pepine CJ, INVEST Investigators.
    Am J Cardiol; 2006 Oct 01; 98(7):890-4. PubMed ID: 16996868
    [Abstract] [Full Text] [Related]

  • 12. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
    de Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Devereux RB.
    Circulation; 2005 Apr 19; 111(15):1924-31. PubMed ID: 15837945
    [Abstract] [Full Text] [Related]

  • 13. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ, INVEST Investigators.
    Am Heart J; 2008 Aug 19; 156(2):241-7. PubMed ID: 18657652
    [Abstract] [Full Text] [Related]

  • 14. [Impact of overweight on clinical outcomes in patients undergoing coronary revascularization].
    Kang JP, Ma CS, Lü Q, Nie SP, Liu XM, Liu XH, DU X, Hu R, Dong JZ, Chen F, Lü SZ, Gu CX, Huang FJ, Wu XS.
    Zhonghua Yi Xue Za Zhi; 2010 May 25; 90(20):1381-4. PubMed ID: 20646625
    [Abstract] [Full Text] [Related]

  • 15. The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery.
    Mullen JT, Moorman DW, Davenport DL.
    Ann Surg; 2009 Jul 25; 250(1):166-72. PubMed ID: 19561456
    [Abstract] [Full Text] [Related]

  • 16. Impact of body mass index on the five-year outcome of patients having percutaneous coronary interventions with drug-eluting stents.
    Sarno G, Räber L, Onuma Y, Garg S, Brugaletta S, van Domburg RT, Pilgrim T, Pfäffli N, Wenaweser P, Windecker S, Serruys P.
    Am J Cardiol; 2011 Jul 15; 108(2):195-201. PubMed ID: 21529741
    [Abstract] [Full Text] [Related]

  • 17. Impact of neurohormonal blockade on association between body mass index and mortality.
    Kennedy LM, Anker SD, Kjekshus J, Cook TJ, Willenheimer R.
    Int J Cardiol; 2007 Jun 25; 119(1):33-40. PubMed ID: 17052777
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study.
    Othman M, Kawar B, El Nahas AM.
    Nephron Clin Pract; 2009 Jun 25; 113(1):c16-23. PubMed ID: 19590231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.